Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
17%(1 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_2
5
63%
Ph phase_1
3
38%

Phase Distribution

3

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
5(62.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(6)
Terminated(2)

Detailed Status

Completed6
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
85.7%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (37.5%)
Phase 25 (62.5%)

Trials by Status

withdrawn113%
completed675%
terminated113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_2

Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)

NCT03130790
completedphase_2

Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer

NCT03093870
terminatedphase_1

Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC

NCT02992340
completedphase_2

Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer

NCT03231176
completedphase_1

Open, Single-dose/-Period Study to Assess Mass Balance Recovery, Metabolite Profile/Identification of 14C-Varlitinib

NCT03368846
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03130790Phase 2

Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)

Completed
NCT03093870Phase 2

Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer

Completed
NCT02992340Phase 1

Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC

Terminated
NCT03231176Phase 2

Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer

Completed
NCT03368846Phase 1

Open, Single-dose/-Period Study to Assess Mass Balance Recovery, Metabolite Profile/Identification of 14C-Varlitinib

Completed
NCT03082053Phase 1

A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours

Completed
NCT02609958Phase 2

ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy

Completed
NCT03129074Phase 2

Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8